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Abstract: Cystic fibrosis (CF) is a monogenic autosomal recessive disorder caused by mutations
in the CFTR gene. There are at least 346 disease-causing variants in the CFTR gene, but effective
small-molecule therapies exist for only ~10% of them. One option to treat all mutations is CFTR
cDNA-based therapy, but clinical trials to date have only been able to stabilise rather than improve
lung function disease in patients. While cDNA-based therapy is already a clinical reality for a number
of diseases, some animal studies have clearly established that precision genome editing can be
significantly more effective than cDNA addition. These observations have led to a number of
gene-editing clinical trials for a small number of such genetic disorders. To date, gene-editing
strategies to correct CFTR mutations have been conducted exclusively in cell models, with no in vivo
gene-editing studies yet described. Here, we highlight some of the key breakthroughs in in vivo and
ex vivo gene and base editing in animal models for other diseases and discuss what might be learned
from these studies in the development of editing strategies that may be applied to cystic fibrosis as
a potential therapeutic approach. There are many hurdles that need to be overcome, including the
in vivo delivery of editing machinery or successful engraftment of ex vivo-edited cells, as well as
minimising potential off-target effects. However, a successful proof-of-concept study for gene or base
editing in one or more of the available CF animal models could pave the way towards a long-term
therapeutic strategy for this disease.
Keywords: gene editing; base editing; cystic fibrosis; AAV; ribonucleotide particle; guideRNA;
CRISPR; Cas9
1. Introduction
Cystic fibrosis (CF) is a monogenic autosomal recessive disorder caused by mutations in the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) gene which encodes a chloride/bicarbonate
channel expressed on the apical surface of secretory cells. Lack of CFTR activity results in multiorgan
dysfunction and ultimately mortality from respiratory sequelae. For more than seven decades,
therapies for CF focused on treatment of the symptoms rather than the origin of the disease which is
the CFTR protein dysfunction [1]. However, since 2011, a number of small-molecule therapies known
as potentiators and correctors have been developed and licenced that can functionally correct at least 33
different CF-causing mutations [2], accounting for 90% of individuals with CF. However, based on the
March 2019 data from cftr2.org [3], this still means 90% of disease-causing variants cannot be corrected
by any available small-molecule therapies.
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An alternative therapeutic approach that has been extensively studied over the last 25 years
is the use of the CFTR cDNA, delivered directly to the lung, to complement the genetic defect in
CFTR. This approach could potentially be curative, at least for CF lung disease, in a manner that is
independent of the disease-causing variants. However, after more than 20 clinical trials, the only
clinical benefit reported so far has been a stabilisation of lung function in patients who received at least
nine doses of CFTR cDNA delivered by cationic liposomes over a 12-month period [4]. In contrast,
both in vivo and ex vivo gene therapy approaches have been very successful in a wide range of other
diseases over the same time frame [5]. It is not clear why CFTR cDNA-based therapy has not yet been
successful, but a number of studies discussed in detail below have shown that precision editing of the
genome can be more effective than cDNA addition, at least in animal models [6,7].
So, could the precision repair of CF-causing variants be a feasible alternative to cDNA addition?
Perhaps the first question to address is how such changes can be made in the genome in the first
instance. The magnitude of the challenge was succinctly captured by Joshua Lederberg in his 1959
Nobel Prize Lecture, where he stated “The ignis fatuus of genetics has been the specific mutagen,
the reagent that would penetrate to a given gene, recognize and modify it in a specific way” [8].
Having acknowledged that it may be possible to exploit base-pairing to potentially find a target site in
a genome, and that it would need to be highly specific to avoid off-target effects, he also noted that ‘no
chemical reagent capable of substituting one nuclein for another in the structure of existent DNA’ had
yet been recognised.
Over the next sixty years, many reagents were developed, based partly on Lederberg’s discoveries
concerning genetic recombination, to create targeted, precise and permanent changes to the cellular
genome, culminating in the ability to generate mice from ES cells engineered with precise modifications
in their genome [9]. However, the efficiency of this approach was considered too low for therapeutic
application. It took a key proof-of-concept experiment from Maria Jasin that a targeted double-stranded
break (DSB) could substantially increase editing efficiency [10], and the development of a new set of
synthetic reagents called zinc finger nucleases (ZFNs) [11] to lay the foundations for therapeutic editing.
But it would take another decade before fully programmable ZFNs were used to correct a disease-causing
mutation in human cells [12]. The ZFNs catalyse the initial step in gene repair, the formation of the
DSB, which can then be repaired using sequence information from an exogenous donor molecule to
introduce the desired change in the genome mediated by the cellular homology-directed repair (HDR)
pathway. Subsequently, the TAL effector nucleases (TALENs) and the Clustered Regularly Interspaced
Short Palindromic Repeats (CRISPR) encoded, RNA-guided Cas family of nucleases have provided
a diverse number of “specific mutagens” for efficient DNA repair, or, as we now know it, precision
gene editing (reviewed in [13–15].
While gene editing is already being evaluated in a number of FDA-approved clinical trials,
there are still many challenges to be addressed. First, DSBs created by ZFNs, TALENs and CRISPR
nucleases are not always repaired via the HDR pathway which is necessary for precision editing,
rather they can also be repaired by a second pathway known as non-homologous end-joining (NHEJ)
which can result in unwanted insertions or deletions (referred to as indels) which can reduce the overall
effectiveness of the editing process. Second, each of the systems can cause unwanted DSBs at other sites
in the genome which share substantial homology to the target site. The repair of these DSBs can give
rise to potentially disruptive indels at these sites, or in some cases trigger genomic rearrangements [16].
Several other challenges exist in the therapeutic development, not least the delivery of gene-editing
reagents to the correct target cells in vivo, the ability to efficiently engraft cells which are edited ex vivo,
and the possibility of immune responses to editing tools in vivo [17,18] which may restrict options
for repeated rounds of editing. Finally, given that most monogenetic diseases are usually caused by
a wide range of variants within a single locus, there has been substantial focus on strategies which can
correct a large number of variants with a single set of reagents. Such strategies may be required for
clinical application.
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In this review, we highlight some of the key breakthroughs that have been made during the
development of gene editing for other diseases, and discuss how they might be applied to cystic
fibrosis from a therapeutic perspective. The impact of gene editing on the study of cystic fibrosis [19],
other gene-based approaches to treating CF [20,21] and the ethics of somatic cell editing [22] are
discussed elsewhere.
2. In Vivo Editing—From Mouse to Man in Six Years
In this section, we introduce the first in vivo demonstration that gene editing could correct
a disease-causing mutation in a mouse model of haemophilia B in 2011 and discuss how this laid the
foundation for a number of therapeutic gene-editing trials in humans just six years later. We also
consider how lessons from these studies might be applied to the development of gene editing as
a therapeutic approach for CF.
Haemophilia B is a chronic liver disease caused by mutations in the F9 gene, leading to a severe
depletion of coagulation factor IX protein. Consequently, blood clotting cannot be properly regulated
in response to injury, resulting in continuous bleeding that can be difficult to control. The disease
can be managed by regular intravenous injections of recombinant factor IX, so long as circulating
levels of protein are maintained at ~5% of the normal value. As with the majority of genetic disorders,
haemophilia B can be caused by any one of a large number of different variants within the target gene.
While early gene-editing studies with zinc finger nucleases (ZFNs) showed that it was feasible to correct
essentially any single disease-causing variant by the donor-dependent HDR pathway for a number of
cell models of genetic disease [23,24] including the F508del variant in CFTR [25], this approach does
not allow for the complete coverage of the wide spectrum of disease-causing variants.
Faced with the challenge of developing multiple ZFN/donor combinations for each disease-causing
mutation in the human F9 gene, Kathy High and colleagues [6] used ZFN-HDR with a novel form of
donor widely known as a superexon, or partial cDNA. As shown in Figure 1, they created a donor
comprising exons 2 to 8 (where 95% of the Hb-causing mutations are found), flanked by a splice acceptor
and a polyA site, and containing homology arms of ~800 bp either side of the construct. They designed
a pair of high-specificity ZFNs to introduce a targeted DSB in the first intron of the F9 gene to drive the
precise and stable integration of the SA-superexon-polyA donor into the genome, which would in turn
yield the production of a full-length and functional mRNA. In principle, this approach could correct
any mutation localised downstream of exon 1.
When evaluated in human hepatocyte cell lines, they observed evidence of ZFN DSB formation as
measured by indels in 45% of alleles, and superexon integration in 17% of alleles. For assessment in vivo,
a humanized mouse model of haemophilia B was used containing the hF9 gene with a premature stop
codon in exon 6 (Y155X). Mice received intraperitoneal injections with two different AAV8 vectors,
one to deliver the ZFN pair and the other one to deliver the superexon donor. This resulted in a targeting
efficiency of ~2% in liver which was stable for at least one month post-injection, and circulating levels
of hF.IX of 2 to 3% of wild-type level which was sufficient to restore normal haemostasis. Two types of
off-target effects were observed in this study. First, the ZFN pair created a low level of indels at one of
the 20 potential off-target sites. Second, some random adeno-associated virus (AAV) integration events
were observed in the mouse genome though not at, or adjacent to, known oncogenic sites, and some
direct AAV vector integration was found in the cut site [6].
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Figure 1. Schematic overview of zinc finger nuclease (ZFN)-mediated homology-directed repair (HDR).
Upper panel: superexon donor with homology arms, SA, exons 2–8 fused as partial cDNA and poly A.
Middle panel: ZFNs create DSB in intron 1 which triggers strand invasion of donor leading to HDR.
Lower panel: superexon incorporated into the genome such that mRNA splices from endogenous exon
1 to superexon 2–8. The expression of the corrected mRNA is driven by the endogenous promoter.
Adapted from [6].
Building on observations from this study, Barzel and colleagues [26] developed a novel strategy
to determine if a hF9 superexon could be expressed from an alternate genomic locus as a step towards
a universal platform for expression of any secreted protein. They chose the Alb locus in part due to its
strong liver-specific promoter, postulating that even a low level of integration could enable high levels of
superexon encoded protein production. They designed their targeting construct to avoid the disruption
of albumin production by fusing a 2A peptide linker to the F9 cDNA, integrating the construct just
upstream of the albumin stop codon [26]. With safety as a major concern for the development of
a platform suitable for clinical use, they chose an integration strategy that was driven solely by the
homology arms and the AAV vector; no ZFNs or other nucleases were used. The absence of site-specific
nucleases may account for the relatively low level of integration observed; only 0.5% of the albumin
alleles in hepatocytes were targeted when the AAV9-hF9 vector was administered to neonatal and adult
mice. However, even with this low level of site-specific integration, the hF.IX plasma level was found
to be 7 to 20% of normal and the expression was both stable, and restored normal coagulation [26].
As a further step towards clinical development, High and colleagues demonstrated the versatility
of the Alb locus as a safe harbour for superexon transgene expression. They showed that any one
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of a number of different human cDNA sequences encoding essential secretory enzymes could be
integrated using the same ZFN pair to create a targeted DSB in intron 1 of the Alb locus to promote
integration; an added advantage was that the desired transgene-targeting constructs could integrate
by either HDR or NHEJ [27]. The ability to integrate by both mechanisms, is an important design
feature as it enables integration to occur not only in dividing cells (where HDR is active during the
S/G2 phase of the cell cycle), but also in non-dividing cells where only the NHEJ pathway is active.
Another feature of the design is that the “fusion transcript” created by the splicing of exon 1 from
the endogenous Alb locus to the integrated superexon means that the proteins were synthesised with
the albumin signal peptide. This signal peptide directs the secretion of the proteins from the liver
cells, but it is subsequently removed, therefore limiting its impact on the protein of interest’s function.
Other strengths of this approach are the fact that the same ZFN pair could be used to stably integrate the
superexon of essentially any secretory protein. Subsequently, proof-of-concept studies have established
that this platform can correct several lysosomal storage diseases including Mucopolysaccharidosis Type
II (Hunter syndrome) [28] and MPS I (Hurler syndrome) [29]. These experiments culminated in the
approval of two human in vivo gene-editing trials for MPS I (NCT02702115) and MPSII (NCT03041324),
with Brian Madeux becoming the first person to receive gene-editing agents in November 2017, just six
years after the first published in vivo data from a mouse model.
Towards In Vivo Editing with CFTR Superexons to Correct Multiple CF-Causing Variants
The superexon technique could be very useful to correct CF-causing variants, though not
necessarily from the Alb locus. For example, 92% of all CF-causing alleles (representing 64% of known
CF-causing variants) could be corrected with a superexon donor comprising exons 11 to 27, a suitable
splicing acceptor site and flanked by homology arms. Such a construct would be small enough to be
delivered by AAV vectors, similar to those used in the studies shown above. Proof-of-concept that
ZFNs and such a CFTR superexon could correct the F508del variant was reported by Toni Cathomen
and colleagues in a bronchial epithelial cell line [30]. Although the efficiency was low, the isolation of
edited cells confirmed that the superexon had been precisely integrated into the CFTR locus by HDR
and could functionally restore CFTR ion channel activity.
Several options to substantially increase the efficiency of superexon integration have been described
using NHEJ-based integration strategies. For example, the CRISPR-based homology-independent
targeted integration (HITI) strategy which preferentially integrates the superexon in the correct
orientation was used to successfully restore a large deletion in the Mertk gene in a rat model of Retinitis
pigementosa [7]; we have outlined a HITI-based strategy to correct CF variants with a superexon
11–27 donor [22]. Other potential CRISPR-based methods which may prove suitable are “knock-in
blunt ligation” (KiBL) [31] and targeted integration with linearised dsDNA (TILD) [32].
Another challenge for CF is that a superexon 2–27 donor, to correct virtually all known CF-causing
variants, would be slightly too large for delivery by standard AAV vectors. However, other non-viral
and viral delivery approaches may be suitable (see [22]), including large capacity helper-dependent
adenovirus vectors (HD-Ad) which have been successfully used to deliver the CFTR cDNA to lung basal
cells [33]. Indeed, these HD-Ad vectors have recently been used to drive the stable integration of CFTR
cDNA into the AAVS1 safe harbour site using TALENs [34] or Cas9/gRNA [35]. Moreover, the editing
events which drive integration result in the concurrent elimination of TALEN/Cas9 expression,
thus potentially reducing off-target effects and risk of immune response to editing machinery.
3. Ex Vivo Approaches for Gene Editing in Animal Models
An alternative to in vivo gene editing is to remove target cells from a patient, edit them ex vivo
in a controlled laboratory setting and then reimplant them. This autologous ex vivo cDNA addition
approach is already clinically well established for a small number of genetic diseases of the immune
system [36]. The use of ex vivo gene editing offers a number of potential advantages over in vivo
editing such as the potential for selection to enrich edited populations of cells, and the assessment
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of off-target effects prior to implantation. There are several challenges in developing an autologous
gene-edited cell-based therapy for CF, but a recent review article suggests delivery and engraftment
may ultimately be feasible [37]. So, here, we focus on some of the editing strategies which are being
explored for other diseases where the delivery and engraftment route is well understood, and ask what
lessons can be learned in order to develop editing for CF.
X-linked chronic granulomatous disease results in a severe malfunction of the immune system
and is caused by mutations in a number of different genes which encode subunits of the NADPH
oxidase complex. If NADPH oxidase cannot assemble or function properly, phagocytes are unable to
kill foreign invaders and neutrophil activity is dysregulated, leaving affected individuals vulnerable
to many types of infection and excessive inflammation. The disease can be treated by autologous
gene-modified cells in combination with nonmyeloablative conditioning. However, at least three
of 13 patients who have undergone this procedure developed myelodysplastic syndrome due to
insertional activation of MDS1–EVI1 [38].
This prompted Malech and colleagues [39] to develop a strategy for ZFN-targeted integration of
the gp91phox cDNA into the AAVS1 safe harbour locus in human CD34+ hematopoietic stem and
progenitor cells (HSPCs). Optimal conditions for editing occurred when HSPCs were electroporated
with mRNAs encoding the ZFNs, then immediately transduced with an AAV6 vector containing the
gp91phox expression construct under the control of the MND promoter (which drives high levels of
transgene expression in HSPCs). Targeted integration was observed in 7% of alleles, restoring the
overall level of p91phox activity to 15% of that observed in a population of CD34+ HSPCs from healthy
donors. Of note, indels were detected in a further 21% of AAVS1 alleles but are not predicted to have
a deleterious effect. To determine the effects in vivo, an unenriched population of ZFN/donor-treated
cells were transplanted into immune-deficient NOD-scid IL2Rγnull (NSG) mice. At eight weeks
post-transplant, high levels of engraftment were detected with >10% of the CD45+ cells derived from
the ZFN/donor-treated population expressing gp91 [39]. Given that all the genome-editing reagents in
the study can be produced to GMP standards, this approach could be suitable for clinical development.
Towards Ex Vivo Editing with CFTR
While delivery and engraftment may ultimately be feasible [22,37], what are the ex vivo editing
options for CF? An early study established the feasibility of integrating the whole CFTR cDNA into
the CCR5 safe harbour locus using ZFNs in human iPS cells, resulting in stable expression of mature
CFTR band C protein [40]. In addition, several groups have successfully used ZFNs, TALENs and
CRISPR to correct individual CF-causing mutations in human iPS cells and confirmed that this
restores CFTR activity [41–44]. However, in all cases, efficiency was relatively low and even though
selection, enrichment and differentiation strategies were successfully developed, these strategies may
be challenging to scale up for clinical development.
Recently, Porteus and colleagues [45] have taken a different approach, avoiding iPSc and
enrichment strategies, and focusing directly on developing the high efficiency editing of a single
CF-causing mutation in primary upper airway basal stem cells (UABCs). HDR editing was performed
by electroporation of Cas9 and gRNA as a ribonucleoprotein (RNP) complex, immediately followed
by transduction with an AAV6 vector carrying the correction template. Under optimal conditions,
precision editing was observed in 43% of alleles [45]. This high efficiency editing also resulted in
a high level of restoration of CFTR functional activity. While their feeder-free, selection-free system
is compatible with a clinical approach for autologous cell-based therapies for CF, it should be noted
that the optimal level of precision repair by HDR (43%) was accompanied by an almost equally high
level of on-target NHEJ events (38%). While a number of FDA-approved drugs have been shown
to improve the HDR:NHEJ ratio [46], it may be time to consider an alternative gene-editing strategy
which can yield very high levels of the on-target editing of individual mutations, but with NHEJ levels
at least 10-fold lower than conventional HDR. This new technique, first described in the genome of
mammalian cells in 2016, is known as base editing.
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4. DNA Base Editing
DNA base editing is a novel genome-editing technique that allows the direct conversion of cytosine
to thymine, or adenine to guanine in genomic DNA, in a programmable manner, without generating
DSBs. The process requires no donor DNA template and, as it does not rely on HDR, it can occur at
all stages of the cell cycle, making it suitable for use in non-dividing cells. More than 50% of known
CF-causing SNPs in CFTR (see Figure 2), which equates to ~12% of alleles in the CFTR2 database [3],
are caused by T>C, G>A, C>T or A>G changes. If the T>C or G>A variants on the coding strand are
located in a suitable editing window relative to a functional protospacer adjacent motif (PAM) sequence
(see Figure 3), then they could be corrected by base editing with very low levels of unwanted indels.
For the C>T and A>G variants, the editing would have to be initiated on the opposite strand, again
with a requirement that the target base is located in a suitable editing window relative to a functional
PAM sequence. Here, we describe the two major classes of base editors and selected experiments
where base editing has been used to establish therapeutic proof-of-principle for this approach in mouse
models of a number of genetic diseases.
Figure 2. Distribution of cystic fibrosis-causing variants. (A) According to the Variant List History
from 11 March 2019 available on the CFTR2 database (https://www.cftr2.org/), there are 346 CF-causing
variants distributed into three main categories: point mutations (66%), insertions/deletions (Indel,
27%) and duplications (7%). (B) Of all the point mutations listed on the CFTR2 database, 46% can
potentially be corrected using Adenine Base Editing (ABE) and 15% using cytosine Base Editing (CBE).
This prediction only takes into account the nucleotide change that causes the mutations and it does not
necessarily mean a suitable PAM sequence is located at the correct spacing from the editing window.
Figure 3. Schematic of base editing. Depending on the base editor used (CBE or ABE),
cytosine (C, in blue) or adenine (A, in blue) in a ~5-nt editing window (dashed box) on the non-target
strand can be deaminated and changed to a uracil or inosine (not represented), respectively. Nicking of
the target strand by nCas9 in the base editor (red triangle) promotes DNA repair and incites the cell
to use edited strand as a template. The uracil is then read as a thymine and the inosine as a guanine,
converting a C-to-T or a A-to-G.
Currently, there are two major types of base editors, those that convert C to T and those that convert
A to G. The DNA base editors typically consist of a fusion protein which comprises a catalytically
impaired CRISPR nuclease and a deaminase enzyme that is specific for single-stranded DNA (ssDNA).
The binding of the Cas9/gRNA to the target DNA strand leads to local denaturation of the DNA,
called R-loop formation, essential for deamination. The deamination occurs in the non-targeted
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DNA strand in a restricted activity window of ~5 nucleotides in the ssDNA leading to a base change
(see Figure 3). As detailed below, further modifications have been made to optimise the base editing
window and increase the fidelity and efficiency of base editing.
4.1. Cytosine Base Editors
The first programmable base editor system to be developed for DNA was a fusion of dCas9 and
the APOBEC1 cytidine deaminase which created a cytosine base editor (CBE) that could deaminate
the amine of the target cytosine in positions 4–8 of the ssDNA on the non-target strand (see Figure 3),
generating uracil [47]. This creates a U:G mismatch which is subsequently converted to a U:A base
pair, or restored to a C:G by cellular DNA repair pathways. When DNA repair of the U:A base pair
occurs, the uracil base is read as a thymine for both transcription and DNA replication. While the
first version of the cytosine base editor (BE1) worked with an editing efficiency of 25–40% in vitro,
Liu and colleagues observed much lower activity in human cells of 0.8–7.7%. The authors attributed
this decrease to the cellular base excision repair (BER) pathway in which the uracil N-glycosylase
(UNG) enzyme recognises the U:G mismatch intermediate and efficiently reverts it back to a C:G pair.
To counter this, their second-generation cytidine base editor (BE2) also included an additional fusion
domain comprising a uracil N-glycosylase inhibitor (UGI) to block BER. Replacement of dCas9 with
Cas9 nickase (to create BE3) resulted in cutting of the non-edited strand of the DNA which favours the
repair of the mismatch U:G to U:A (the desired edit) over the DNA repair back to C:G (the original
unedited target).
An analogous cytosine base editing system was described by Nishida and co-workers [48].
Their system, called Target-AID, is similar to BE3 but instead of using APOBEC1 this group used
cytidine deaminase 1 (CDA1) which acts in positions 2–4 of the ssDNA. Both groups [47,48] noted that,
in some cases, C to G and C to A transversions are detected at the editing site, rather than the desired
C to U transition, and these are most likely a consequence of BER, resulting in the insertion of a G or A
residue. The addition of a second UGI domain to BE3 (to create BE4), was shown to reduce this [49].
Additional refinements to BE have been reported including modifications to (1) reduce indels
by fusing the bacteriophage Mu-derived Gam protein (Mu-GAM) to BE4 to generate BE4-Gam [49];
(2) limit off-targets by the development of a high-fidelity version of BE3 [50]; (3) eliminate bystander
products (edits of cytidines adjacent to the target residue) by introducing mutations in the APOBEC1
domain to narrow the base editing window (YE1-BE3, YE2-BE3, YEE-BE3 and eA3A-BE) [51] or,
in contrast, increase their occurrence with a broader editing window (BE-PLUS) [52]; (4) the recognition
of a wider range of targets by engineering variants of both SaCas9 and SpCas9, capable of recognising
specific non-NGG PAMs (SaBE3, Sa(KKH)-BE3, VQR-BE3, VRER-BE3 and EQRBE3) [51]; or (5) a broad
range of PAMs with an evolved variant of SpCas9-BE called BE-xCas9(3.7) [53]; (6) improve intracellular
expression and nuclear localisation of the base editor (BE4max) [54]. Of note, Cas12a (Cpf1) variants of
the C to U base editor with a broad PAM specificity have also been described [55].
4.2. Adenine Base Editors
A limitation of C to U base editing is that the majority of disease-causing SNPs originally occurred
as a consequence of C to U deamination events, which often result in the formation of premature
termination codons (PTCs—see Figure 2). Thus, there was a major incentive to develop a base editing
strategy that could convert thymine to cytosine directly, or convert adenine to guanine on the opposite
strand of DNA which would have the same effect as converting T to C (see Figure 3). In theory,
the simplest approach would be the enzymatic deamination of adenine which would form inosine (I),
a naturally occurring base which has a base pairing preference for guanine. The ability to correct A:T
to G:C would have great therapeutic potential for genetic diseases. Indeed, it could correct nonsense
mutations such as W1282X mutation, one of the most common CF-causing mutations and for which
there are no specific drugs available.
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The major obstacle to the development of the adenine base editors is that in Nature, there is
no known adenine deaminase able to work in a DNA backbone. To address this challenge, Liu and
co-workers [56] evolved one half of the dimeric Escherichia coli tRNA adenosine deaminase enzyme
(TadA) that works in an RNA backbone in its bacterial host to function in a DNA context for genome
editing. Then, to create a targetable adenine base editor (ABE), they fused a wild-type non-catalytic
TadA monomer and an evolved TadA monomer with a Cas9 nickase. Using a number of target genes
in human cell lines, they successfully demonstrated highly efficient base editing in a small window,
converting any A:T to G:C in the positions ~4–7 (see Figure 3). Of several variants they created,
ABE7.10 is the most efficient, whereas ABE7.9 and ABE6.3 can also edit in positions 8 or 9.
Adenine base editing shows a very high level of editing precision with A to C or A to T transversions
observed at very low levels, most likely due to the much weaker ability of cells to remove inosine
than uracil from DNA [57]. Moreover, the reduced incidence of inosine excision from edited strand
prevents nicking of this strand which is thought to explain why A to I base editing shows much low
indel frequencies compared to C to U base editing. Off-target studies in mutant mice suggest high
specificity of ABE7.10, but there may be a low level of deamination from base editors that occurs in the
absence of DNA-binding due to random encounters between deaminase domain of ABE and transient
ssDNA intermediates [58].
5. DNA Base Editing—Proof-of-Concept Disease Models
Even though DNA base editing is a much more recently described technique than CRISPR/Cas9
gene editing, there are already several studies exploring its therapeutic potential for a diversity of
diseases. Here, we describe three examples of in vivo base editing using either cytosine or adenine base
editors to correct mutations that cause (5.1) Duchenne muscular dystrophy (Dmd); (5.2) phenylketonuria
(PKU); or (5.3) hereditary tyrosinemia type I (HTI) in mouse models. We also describe two different
studies that use cytosine base editing to inactivate the Pcsk9 gene by introducing PTCs and show that
this can permanently reduce blood cholesterol levels (5.4). These studies yield considerable insights
into the in vivo use of base editing in terms of efficiency, indel frequency, off-target effects and delivery
systems, all of which may be useful in developing the use of base editing for study and potential
treatment of cystic fibrosis.
5.1. Adenine Base Editing of a Dmd Mouse Model
Duchenne muscular dystrophy is caused by mutations in the Dmd gene that encodes a protein
called dystrophin expressed predominantly in skeletal and heart muscles cells. The loss of dystrophin
leads to muscle atrophy and prevents Dmd patients performing the most basic tasks such as walking,
standing or sitting, and as the disease progress, young boys and men affected by this disease die by
respiratory or cardiac failure.
To evaluate the therapeutic potential of base editing in vivo, Ryu and colleagues [59] delivered
ABE7.10 using adeno-associated virus (AAV) to a mouse model of Dmd [60] that harbours a premature
stop codon (Q871X) in the Dmd gene (see Figure 4). Given the limited packaging capacity of the
adeno-associated virus of ~4.7 kb, the construct encoding ABE7.10 (its ORF alone is ~5 kb) plus its
sgRNA had to be delivered in two parts using a dual trans-splicing adeno-associated virus (tsAAV)
vector system. This system consists of two AAV vectors encoding either the N-terminal or C-terminal
of ABE7.10 flanked by inverted terminal repeat (ITR) sequences. Following the transduction of cells by
both vectors, the two mRNAs can trans-splice, resulting in expression of the full-length ABE7.10 protein
and production of the guide RNA to form the base editing complex. Following the intramuscular
administration of the vector system into the tibialis anterior muscle of the Dmd knockout mice,
the level of precise A to G base substitutions were assessed by targeted deep-sequencing eight weeks
post-injection. The PTC was converted to the glutamine codon with a frequency of 3.3 ± 0.9% and,
more importantly, no unwanted indels or off-target events were detected at homologous sites which
contained up to three mismatches. Remarkably, the Dmd-targeted tsAAV:ABE restored dystrophin
Genes 2019, 10, 387 10 of 17
expression in 17 ± 1% of myofibers as evaluated through histological analysis of the tibialis anterior
muscle, a level which is sufficient to improve muscle function. The elevated level of functional
correction relative to the frequency of editing may be due to a selective advantage for corrected
myofiber cells in vivo.
Figure 4. Base editing options to different diseases. Representation of the four different codons, X871,
S263, T286, W159, responsible for causing Duchenne Muscular Dystrophy (Dmd), Phenylketonuria
(PKU), Human Tyrosinemia type I (HTI) and Hypercholesterolemia, respectively. Nucleotide conversion
is represented in blue and the base editor used in the studies to correct or introduce the mutation is
represented in red.
5.2. Treatment of a Metabolic Disease by Cytosine Base Editing
Phenylketonuria is an autosomal recessive metabolic liver disease in which the impaired activity
of the enzyme phenylalanine hydroxylase (PAH) leads to a decreased metabolism of phenylalanine
(L-Phe) and its accumulation in blood, resulting in systemic hyperphenylalaninaemia. If PKU is not
detected early, or not treated correctly with a phenylalanine-free diet, then patients, usually infants,
will suffer from severe retardation, microcephaly, and seizures. Mice homozygous for mutations in the
Pah gene fed on a normal diet which contains phenylalanine develop similar symptoms making them
a suitable animal model to study PKU [61]. These Pahenu2 mice harbour a point mutation T:A to C:G
(F263S) in exon 7 of the Pah gene that abolishes PAH enzyme function and causes abnormally elevated
L-Phe levels (≥1500 µmol/L), compared to normal levels of ~120 µmol/l.
Villiger and colleagues [62] used a split AAV vector system to deliver the cytidine base editor
nSaKKH-BE3 which includes a smaller Cas9 nickase from Staphylococcus aureus (Sa). The nSaKKH-BE3
base editor was split in two parts, p.N-int-BE3 containing the N-terminal half of the BE gene and
p.C-int-BE3.sgRNA, which contained the C-terminal half of the BE gene, red fluorescent protein
(RFP) sequence and the sgRNA specific for Pahenu2. In both cases, expression was driven by
a synthetic liver-specific promoter P3 and constructs were packaged into pseudotyped AAV2/8 vectors
(AAV8.N-int-BE3 and AAV8.C-int-BE3.sgRNA). Adult mice between eight and ten weeks of age
received tail-vein injections of either low (5 × 1010 vector genomes (vg)) or high dose (5 × 1011 vg)
per mouse. As a control, the AAV8.C-int-BE3.sgRNA was replaced by a modified vector lacking the
Pahenu2-specific sgRNA (AAV8.C-int-BE3). The specificity of the P3 promoter was confirmed by the
detection of RFP expression only in liver and not in other organs. In the low-dose group, blood L-Phe
levels were moderately reduced to ~1000 µmol/L at eight weeks post-injection, while, in the high-dose
group, L-Phe levels were reduced to physiological normal levels of ≥120 µmol/L after only six weeks
post-injection and remained at this level for up to 26 weeks.
Quantification and precision of Pah gene correction rates were assessed by the high throughput
sequencing (HTS) of PCR amplicons from genomic DNA [62]. The editing levels in mice measured at
4, 8, 14, and 26 weeks post-injection showed 10, 19, 22 and 25% C-to-T correction rates, respectively,
whereas indels rose to a maximum of 10% at 26 weeks post-injection. Of note, editing at the DNA level
gave rise to a higher level of edited transcripts, with levels of 17, 34, 39 and 44% at corresponding time
time-points. Analysis of whole liver lysates showed the restoration of wild-type enzyme activity that
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correlated to correction rates of mRNA and genomic DNA. Furthermore, PKU-associated phenotypes
such as reduced weight and hypopigmentation were reversed in corrected mice. Ten computationally
predicted off-target loci, were analysed in mice eight weeks after the administration of a higher dose
of AAV and no C to T conversion or indels above background were detected by HTS. In addition,
no indication of excessive DNA damage or cell proliferation after prolonged exposure to low levels
of base editors was observed [62]. Together, this approach provides proof-of-principle that the
AAV-mediated delivery of base editing machinery allows the rescue of the inborn metabolic disease of
liver, an adult tissue with limited proliferative capacity.
5.3. Adenine Base Editing of a Mouse Model of Hereditary Tyrosinemia I
Hereditary tyrosinemia type I is a fatal genetic disease caused by loss-of-function of
fumarylacetoacetate hydrolase (FAH) enzyme, a key protein in the tyrosine metabolic pathway.
When FAH enzymatic activity is compromised, this leads to the accumulation of toxic metabolic
intermediates which causes hepatocyte apoptosis and, consequently, severe liver damage. The existing
Fahmut/mut mouse model [63] carries a homozygous G-to-A point mutation (A236T) in the last nucleotide
of exon 8 (see Figure 4), resulting in exon skipping and loss of FAH protein. When these mice are
supplemented with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), an inhibitor
of the tyrosine metabolism upstream of FAH, toxin build-up and liver damage is prevented in
these animals.
In an early study using conventional Cas9 gene editing by HDR, it was established that corrected
liver cells have a selective advantage and expand to repopulate the liver [64]. A previously validated
Fah sgRNA from that study, where the disease-causing mutation is located at position 9, and base
editor ABE6.3, which performs better at this position, were used to edit the Fah gene [65]. As noted by
the authors, there is other “A” in the sgRNA position 6 whose editing changes a serine codon into
alanine. This change might not restore splicing but its proximity to the Fah enzyme active site may
compromise enzyme activity and impede the functional rescue of edited hepatocytes. Both ABE6.3 and
Fah sgRNA plasmids were delivered to adult mice liver through hydrodynamic tail vein injection at
day 1. When NTBC supplemented-water was removed at day 6 to promote HTI, there was a rapid loss
of 20% of total body weight in control mice (injected with PBS or ABE6.3 alone), while the injection of
both ABE6.3 and Fah sgRNA rescued weight loss and remained until 106 days after injection without
NTBC treatment. Expansion of corrected hepatocytes, as shown by immunohistochemistry (IHC) of
liver sections with FAH-specific antibody, contributed to the weight loss rescue. This data demonstrates
not only the viability and functionality of ABE corrected hepatocytes at a long-term, but also indicates
that ABE is able to rescue the disease phenotype in vivo.
To understand whether ABE corrects Fah splicing mutation in exon 8 in ABE-treated mice
(post-NTBC withdrawal and hepatocyte expansion), the authors deep-sequenced a genomic region
spanning exon 5 to 9. This data showed a correction rate of 9.5± 4.0% and of 1.9± 0.9% at either position
9 or position 6, respectively. The correction rate at both positions was ~0.1%. The rate of stochastic
insertions and deletions was as low as 0.05% in ABE-treated hepatocytes. Deep sequencing of the four
top-ranking off-target sites showed no A:T to G:C editing in ABE-treated livers. However, the authors
consider that on-target ABE efficiency in vivo is relatively low making the detection of off-target
effects difficult.
To improve editing efficiency, ABE6.3 was used with a codon optimized Cas9 nickase and
a N-terminal nuclear localization sequence (NLS), hereinafter called the RA6.3 base editor. The injection
of RA6.3 and Fah sgRNA in the same animal model showed more FAH+ hepatocytes and higher A to
G correction rate than when ABE6.3 was used, as confirmed by IHC and deep sequencing. The authors
then tested the delivery of RA6.3 mRNA along with a chemically modified sgRNA to the mice liver
trough the tail vein injection of lipid nanoparticle. To measure the initial ABE efficiency, mice were kept
in NTBC treatment to prevent hepatocyte proliferation. The IHC results showed no edited hepatocytes
in control Fahmut/mut mice, while mice injected with both RA6.3 mRNA and Fah sgRNA showed 0.44%
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± 0.28% of edited hepatocytes. This data suggests that the non-viral delivery of ABE is possible in the
adult mouse liver. However, improvements in ABE mRNA stability and delivery vehicles are needed.
Once again, this study shows the potential of ABE to correct A to G point mutations in adult
animal models rescuing the disease phenotype, with a very low rate of indel formation. This study
also demonstrates how improvements in base editors, in combination with better delivery systems,
can increase editing efficiency in vivo.
5.4. Cytosine Base Editing of PCSK9 as a Permanent Therapeutic Approach
High levels of low-density lipoprotein (LDL) cholesterol in circulation is a well-established risk
factor for cardiovascular disease, the leading cause of death worldwide. Currently, the main treatment
for hypercholesterolemia is statins but some patients are intolerant to this drug. An alternative approach
to reduce cholesterol levels is the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9).
This protein has a key role in cholesterol homeostasis by directing membrane-bound LDL receptors
to lysosomal degradation. Individuals with naturally occurring loss-of-function mutation in PCSK9
gene have lower levels of LDL cholesterol compared to general population. Human PCSK9-targeted
therapies, such as monoclonal antibodies and siRNAs, have been used in clinical trials but their benefit
is short and chronic administration is required. Recent studies using CRISPR-Cas9 NHEJ to disrupt
Pcsk9 gene in mouse and human hepatocytes in vivo had demonstrated reduced plasma concentrations
of PCSK9 protein and cholesterol [66,67].
The first study uses cytosine base editor BE3 to disrupt the Pcsk9 gene in adult mice by introducing
a nonsense mutation (W159X) [68]. A single adenoviral vector was used to deliver BE3 and the sgRNA
targeting W159 codon in the Pcsk9 gene (BE3-Pcsk9) and administered through retro-orbital injection
to 5-week-old male C57BL/6J mice. The base editing of the Pcsk9 gene resulted in a reduction of
56 and 28% in the PCSK9 protein and cholesterol plasma levels, respectively, and it greatly increased
hepatic LDL receptor levels. Deep sequencing of the genomic DNA samples from mice five days after
treatment, showed 34% base editing of alleles in the liver and an indel rate of ~1%. These editing
and indel levels were stable for at least four weeks after treatment. It is important to note that other
changes rather than C to T were observed, resulting in missense variants instead of nonsense variants
in some alleles; but, on average, 22% of alleles were precisely edited to W159X. Nine potential base
editing off-target sites were evaluated by deep sequencing in three BE3-Pcsk9-treated and one control
mouse, but no evidence of off-target C-to-T edits, nor indels, were observed.
In a more recent study, researchers generated a knock-in (KI) mouse with liver-specific
expression of human PCSK9 driven by albumin promoter, termed hPCSK9-KI, to model of human
hypercholesterolemia [69]. Results show a hypercholesterolemic phenotype driven by PCSK9 that gets
worse with age, similar to what has been seen in human hypercholesterolemia. Significantly lower
plasma cholesterol levels in hPCSK9-KI but not in control mice, after the administration of evolocumab
(an inhibitor of human PCSK9), support the hypothesis that the hypercholesterolemic phenotype
observed is dictated by the liver-specific expression of human PCSK9. To demonstrate the efficiency of
human PCSK9 gene base editing in this in vivo system, BE3 base editor and a previously validated
sgRNA (therefore termed gMH) were used [68]. This sgRNA has perfect complementarity to the
mouse Pcsk9 locus and one nucleotide mismatch to the human gene. The hPCSK9-KI 10-week-old mice
were injected via tail vein with adenoviral vectors encoding BE3 together with gMH or BE3 alone as
control. Three weeks after injection, it was observed in treated mice that most of the single nucleotide
substitutions were the targeted C to T transitions in both human PCSK9 and mouse Pcsk9 by deep
sequencing of the genomic DNA from liver tissue. Significant reductions were also observed at three
weeks post-injection in (1) circulating levels of both human and mouse PCSK9 protein and (2) total
cholesterol plasma levels. In addition, an increase in LDL receptor-positive cells was detected by IHC
in BE3-gMH injected mice.
Importantly, this study compares the use of the same sgRNA with both CRISPR/Cas9 and base
editing techniques. It shows that base editing can be used in vivo to introduce precise point mutations
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without any detectable off-targets and a significantly lower frequency of indels when compared to
Cas9-mediated genome editing.
5.5. Base Editing as a Therapeutic Option for CF
These studies demonstrate the capacity of both the DNA-specific CBE and ABE proteins to correct
or introduce C to T or A to G point mutations, respectively, which could be applied to a large number of
CF-causing variants. Indeed, base editing of CFTR variants is not a new approach per se, as Rosenthal
and colleagues reported site-specific RNA base editing of the CFTR W496X mRNA which transiently
restored CFTR function in Xenopus oocytes [70], but this may have limited therapeutic application as
it would require long-term expression of the editor and gRNA.
For the correction of CF-causing mutations in genomic DNA, the base editing approach could
be particularly useful for two major categories of mutation, PTCs and certain splicing mutations.
Adenine base editing will convert a PTC to one of four possible codons (TGG = Tryptophan,
CGA/CGG = Arginine, or Glutamine) depending on the sequence of the PTC and which strand
is targeted. Thus, W1282X could be repaired to the wildtype sequence and should therefore restore full
function, whereas G542X would be repaired to a Tryptophan or Arginine codon which should stop
nonsense-mediated decay of the variant mRNA, and make a full-length CFTR protein, but it may show
reduced function due to change in amino acid sequence. It should be noted that the target A residues
for both these mutations lie outside the editing window for currently available ABE proteins.
For the correction of splicing mutations, ABE could in principle repair mutations such as 1717-1G>A
by targeting the coding strand, whereas CBE could repair mutations such as 3272-26A->G by targeting
the non-coding strand (conversion of C to T on non-coding strand would lead to conversion of G to A
on the coding strand).
As discussed in detail above, the base editing approach is compatible with a wide range of
methods including plasmids, RNA molecules, RNP–lipid complexes [71]. It can also be delivered
by AAV, with the base editor cDNA split across two vectors to generate a trans-spliced mRNA.
An advantage relative to gene editing by HDR is that no donor is required, but the downside is that
not all changes can be corrected. Also, the target A or C must be in the correct editing window relative
to the PAM site, but with an increasing range of base editors with altered PAM specificities, this is
becoming less of a challenge. Off-target effects of base editors are less well studied, but in principle
the much lower rate of indels should reduce potential genomic rearrangements, and early studies
suggest that ABE off-targets are lower than CBE in genome DNA [72–74]. Of note, a recent study has
detected the deamination of both cytosines and adenines in the RNA of human cells when treated
with DNA base editors [75]. Even though these base editing-induced RNA edits can occur in both
protein-coding and non-protein coding sequences they are short-lived. The incidence of this RNA
editing can be reduced when base editing is performed with RNPs rather than plasmid encoded base
editors. Moreover, Grünewald and colleagues developed two BE variants that further reduced the
likelihood of RNA editing events.
In summary, there are a broad array of gene-editing techniques available to correct many
CF-causing variants simultaneously using superexon donors or targeted integration of the complete
CFTR cDNA, or both gene and base editing techniques that could be used to precisely repair individual
CF-causing variants. As we approach a situation where small-molecule therapies are potentially
available for more than 90% of CF patients, there is a growing urgency for the development of
therapeutic strategies for people with rarer complex CFTR variants. If it is possible to establish
proof-of-concept in one or more the family of CF animal models for this approach, and determine the
most efficient and safe method of in vivo or ex vivo delivery, then this would pave the way for the
evaluation of a personalised gene or base editing strategy as a potential long-term therapeutic strategy
for this disease.
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